Advancing Evidence in Cabotegravir for HIV Prevention (General)

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of cabotegravir in HIV prevention across a wide range of scientific priorities. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies in diverse populations that can expand real-world knowledge and inform clinical practice.

ViiV ISR Area Of Interest Overview

Drug/Product Alignment

ViiV Products in Scope:	Dolutegravir
Treatment Type:	Treatment
Specify the Treatment Type:

Area of Interest/DataGap Description

Core Focus Area:

Efficacy/Effectiveness, Experience and Preference

Example Research Question(s):

•   What is the efficacy and safety of DTG/3TC in acute HIV infection?
•   What are the treatment outcomes of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals with rapid ART initiation?
•   What is the efficacy and barrier to resistance of DTG/3TC vs BIC/FTC/TAF in treatment-naïve individuals at risk of non-adherence?
•   What is the impact of DTG/3TC on overall health and wellbeing for treatment naive individuals, as determined by patient reported outcomes and/or patient experience?
•   What are the drivers for DTG/3TC decision/choice among treatment naïve individuals and physicians?

Desirable Study Parameters

Populations of Interest:	Treatment Naïve
Geographical Regions:	Global

Version 20250909-disp

- Back to Top -

Advancing Evidence in Cabotegravir for HIV Prevention (General)

ViiV ISR Area Of Interest Overview

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study